We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

49 hedge funds and large institutions have $51.5M invested in NeuBase Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 12 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 2

400% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 6

167% more capital invested

Capital invested by funds: $19.3M → $51.5M (+$32.3M)

96% more funds holding

Funds holding: 25 → 49 (+24)

Holders
49
Holders Change
+24
Holders Change %
+96%
% of All Funds
1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
12
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$7.37M
2
Renaissance Technologies
Renaissance Technologies
New York
+$4.31M
3
Millennium Management
Millennium Management
New York
+$3.31M
4
GC
Greenlight Capital
New York
+$3.05M
5
State Street
State Street
Massachusetts
+$2.08M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$2.64M
2
Squarepoint
Squarepoint
New York
-$449K
3
EI
EAM Investors
California
-$150K
4
Jane Street
Jane Street
New York
-$121K
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$87K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$16.7M +$3.05M +18,238 +24%
BlackRock
2
BlackRock
New York
$8.19M +$7.37M +44,030 +1,692%
Renaissance Technologies
3
Renaissance Technologies
New York
$7.87M +$4.31M +25,730 +135%
Millennium Management
4
Millennium Management
New York
$3.68M +$3.31M +19,794 +1,689%
State Street
5
State Street
Massachusetts
$2.18M +$2.08M +12,440 New
Northern Trust
6
Northern Trust
Illinois
$1.7M +$1.62M +9,700 New
SCM
7
Sio Capital Management
New York
$1.57M +$1.5M +8,970 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$1.34M +$1.14M +6,814 +841%
SFM
9
Sphera Funds Management
Israel
$1.32M +$1.26M +7,500 New
Vanguard Group
10
Vanguard Group
Pennsylvania
$1.13M +$732K +4,374 +213%
N
11
Nuveen
North Carolina
$890K +$849K +5,072 New
EI
12
EAM Investors
California
$756K -$150K -897 -17%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$584K +$556K +3,323 New
Charles Schwab
14
Charles Schwab
California
$382K +$364K +2,174 New
Citadel Advisors
15
Citadel Advisors
Florida
$260K +$248K +1,481 New
OGC
16
Oak Grove Capital
New Hampshire
$246K +$234K +1,399 New
Bank of America
17
Bank of America
North Carolina
$245K +$157K +940 +206%
California State Teachers Retirement System (CalSTRS)
18
California State Teachers Retirement System (CalSTRS)
California
$229K +$218K +1,302 New
Wells Fargo
19
Wells Fargo
California
$220K +$204K +1,220 +3,813%
Two Sigma Advisers
20
Two Sigma Advisers
New York
$216K +$205K +1,227 New
PPCM
21
Pillar Pacific Capital Management
California
$174K – – –
New York State Common Retirement Fund
22
New York State Common Retirement Fund
New York
$139K +$132K +790 New
RhumbLine Advisers
23
RhumbLine Advisers
Massachusetts
$139K +$132K +790 New
Morgan Stanley
24
Morgan Stanley
New York
$132K +$46K +275 +58%
Goldman Sachs
25
Goldman Sachs
New York
$122K +$116K +695 New
1
2 3

NBSE Hedge Fund Activity: Q2 2020 in Review

49 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q2 2020, worth a combined $51.5M — up 167% from $19.3M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new NBSE positions and 6 closed out — a net gain of 24 holders — while 12 added to existing stakes and 2 trimmed.

The largest buyer was BlackRock, adding an estimated $7.37M. The largest seller was OrbiMed, exiting entirely with an estimated $2.64M sold.

  • 49 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q2 2020, up from 25 in Q1 2020.
  • Funds reported $51.5M of NeuBase Therapeutics, Inc. Common Stock stock for Q2 2020, up 167% quarter-over-quarter.
  • 30 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q2 2020 and 6 closed out, a net change of +24 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q2 2020 was BlackRock, an estimated $7.37M added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q2 2020 was OrbiMed, an estimated $2.64M sold.

Based on aggregated 13F filings for Q2 2020.